Mubadala Bio
↗Abu Dhabi, United Arab Emirates
Mubadala Bio is a life sciences company launched in May 2025 by Mubadala Investment Company, an Abu Dhabi sovereign wealth fund. Operating across two core verticals—Integrated Biopharma and Pharma Logistics—the company focuses on local pharmaceutical manufacturing, global distribution, and advancing healthcare solutions across the UAE and internationally. The company manages an integrated portfolio of 10 manufacturing facilities spanning Asia, Africa, and Europe (6 based in the UAE), with cumulative capacity exceeding 2.5 billion tablets and capsules and 120 million IV/injectable formulations annually. Mubadala Bio pursues better health outcomes by ensuring access to essential, high-quality therapeutics, medical devices, and advanced medicines while strengthening drug security and supporting the UAE's economic diversification into knowledge-based life sciences.
CLASSIFICATION
Company Type:CDMO
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Pharmaceutical Manufacturing and Distribution
SIZE & FINANCIALS
Employees:501-1000
Founded:2025
Ownership:subsidiary
Status:operating
FUNDING
Stage:Not applicable (subsidiary of sovereign wealth fund)
Investors:Mubadala Investment Company (Abu Dhabi Government)
PIPELINE
Stage:Commercial (Manufacturing & Distribution)
Lead Drug Stage:N/A - Not a drug development company
Modalities:Small molecule, Hormone therapy, Cell therapy, Gene therapy
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Mubadala Investment Company
Subsidiaries:Kelix Bio (acquired September 2024), Bioventure Healthcare, Gulf Inject, Wellpharma, DiabTec (acquired by Kelix Bio, 2025)
Key Partnerships:National Resilience: Partnership to develop advanced biopharma manufacturing facility in UAE for complex biologics (oncology, autoimmune). First GMP biopharma facility in the region., Khalifa University: Collaboration to advance UAE's biopharma capabilities with Kelix Bio, GlobalOne Healthcare Holding (GHH): Kelix Bio acquired pharma assets: Bioventure, Gulf Inject, Wellpharma (October 2024)
COMPETITION
Position:Emerging - Regional leader in UAE pharma manufacturing
Competitors:Julphar, Arab Pharmaceutical Manufacturing, Regional CDMO/contract manufacturers, International generic pharmaceutical manufacturers
LEADERSHIP
Key Executives:
Dr. Essam Mohamed - Chief Executive Officer
Hamad Husein Al Marzooqi - Deputy Chief Executive Officer
Atif Azeem - Chief Financial Officer
Khalid Abdallah Al-Kaf - General Manager, Pharma Logistics
LINKS
Website:mubadalabio.ae
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Mubadala Bio and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Mubadala Bio. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.